Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Gergely

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
The Journal of Clinical Endocrinology and Metabolism|September 13, 2019
A Novel Anti-CD40 Monoclonal Antibody, Iscalimab, for Control of Graves Hyperthyroidism-A Proof-of-Concept TrialGeorge J Kahaly, Marius Nicolae Stan, Lara Frommer, et al.
European Journal of Drug Metabolism and Pharmacokinetics|August 2, 2023
First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of MHV370, a Dual Inhibitor of Toll-Like Receptors 7 and 8, in Healthy AdultsTamas Shisha, Maximilian G Posch, Jeanette Lehmann, et al.
Transplantation and Cellular Therapy|November 7, 2022
Mocravimod, a Selective Sphingosine-1-Phosphate Receptor Modulator, in Allogeneic Hematopoietic Stem Cell Transplantation for MalignancySimone Dertschnig, Peter Gergely, Jürgen Finke, et al.
The Journal of Biological Chemistry|August 29, 2006
Regulation of CD4 expression via recycling by HRES-1/RAB4 controls susceptibility to HIV infectionGyorgy Nagy, Jeffrey Ward, Dick D Mosser, et al.
Annals of the Rheumatic Diseases|April 8, 2022
Development and preliminary validation of the Sjögren's Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sjögren's syndromeRaphaele Seror, Gabriel Baron, Marine Camus, et al.
Arthritis Research & Therapy|May 12, 2026
Clinical characteristics and response to standard-of-care treatment in systemic lupus erythematosus patients with or without anti-ribonucleoprotein (RNP) antibodies: an Australian, multi-centre cohort studyRangi Kandane-Rathnayake, Rachel Koelmeyer, Shereen Oon, et al.
Annals of the Rheumatic Diseases|November 6, 2023
Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjögren's syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trialThomas Dörner, Martin Kaul, Antónia Szántó, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|October 25, 2019
First-in-human clinical trial to assess pharmacokinetics, pharmacodynamics, safety, and tolerability of iscalimab, an anti-CD40 monoclonal antibodyPascal Espié, YanLing He, Phillip Koo, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|November 21, 2023
Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: A phase 2 randomized studyBaltazar GomezMancilla, Matthew N Meriggioli, Angela Genge, et al.
Annals of the Rheumatic Diseases|February 4, 2017
Pharmacological inhibition of porcupine induces regression of experimental skin fibrosis by targeting Wnt signallingChih-Wei Chen, Christian Beyer, Jun Liu, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
The Journal of Clinical Endocrinology and Metabolism|September 13, 2019
A Novel Anti-CD40 Monoclonal Antibody, Iscalimab, for Control of Graves Hyperthyroidism-A Proof-of-Concept TrialGeorge J Kahaly, Marius Nicolae Stan, Lara Frommer, et al.
European Journal of Drug Metabolism and Pharmacokinetics|August 2, 2023
First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of MHV370, a Dual Inhibitor of Toll-Like Receptors 7 and 8, in Healthy AdultsTamas Shisha, Maximilian G Posch, Jeanette Lehmann, et al.
Transplantation and Cellular Therapy|November 7, 2022
Mocravimod, a Selective Sphingosine-1-Phosphate Receptor Modulator, in Allogeneic Hematopoietic Stem Cell Transplantation for MalignancySimone Dertschnig, Peter Gergely, Jürgen Finke, et al.
The Journal of Biological Chemistry|August 29, 2006
Regulation of CD4 expression via recycling by HRES-1/RAB4 controls susceptibility to HIV infectionGyorgy Nagy, Jeffrey Ward, Dick D Mosser, et al.
Annals of the Rheumatic Diseases|April 8, 2022
Development and preliminary validation of the Sjögren's Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sjögren's syndromeRaphaele Seror, Gabriel Baron, Marine Camus, et al.
Arthritis Research & Therapy|May 12, 2026
Clinical characteristics and response to standard-of-care treatment in systemic lupus erythematosus patients with or without anti-ribonucleoprotein (RNP) antibodies: an Australian, multi-centre cohort studyRangi Kandane-Rathnayake, Rachel Koelmeyer, Shereen Oon, et al.
Annals of the Rheumatic Diseases|November 6, 2023
Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjögren's syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trialThomas Dörner, Martin Kaul, Antónia Szántó, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|October 25, 2019
First-in-human clinical trial to assess pharmacokinetics, pharmacodynamics, safety, and tolerability of iscalimab, an anti-CD40 monoclonal antibodyPascal Espié, YanLing He, Phillip Koo, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|November 21, 2023
Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: A phase 2 randomized studyBaltazar GomezMancilla, Matthew N Meriggioli, Angela Genge, et al.
Annals of the Rheumatic Diseases|February 4, 2017
Pharmacological inhibition of porcupine induces regression of experimental skin fibrosis by targeting Wnt signallingChih-Wei Chen, Christian Beyer, Jun Liu, et al.
Pageof 4